These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

603 related articles for article (PubMed ID: 28407414)

  • 1. Association of glucagon-like peptide-1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system.
    Zimmerman RS; Hobbs TM; Wells BJ; Kong SX; Kattan MW; Bouchard J; Chagin KM; Yu C; Sakurada B; Milinovich A; Weng W; Bauman JM; Pantalone KM
    Diabetes Obes Metab; 2017 Nov; 19(11):1555-1561. PubMed ID: 28407414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.
    Dong YH; Chang CH; Lin JW; Yang WS; Wu LC; Toh S
    Diabetes Obes Metab; 2022 Aug; 24(8):1623-1637. PubMed ID: 35491533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular Outcomes Among Patients with Type 2 Diabetes Newly Initiated on Sodium-Glucose Cotransporter-2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Other Antidiabetic Medications.
    Pineda ED; Liao IC; Godley PJ; Michel JB; Rascati KL
    J Manag Care Spec Pharm; 2020 May; 26(5):610-618. PubMed ID: 32347181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.
    Hussein H; Zaccardi F; Khunti K; Seidu S; Davies MJ; Gray LJ
    Diabet Med; 2019 Apr; 36(4):444-452. PubMed ID: 30653708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes.
    Wang L; Xu R; Kaelber DC; Berger NA
    JAMA Netw Open; 2024 Jul; 7(7):e2421305. PubMed ID: 38967919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective UK cohort study.
    Anyanwagu U; Mamza J; Donnelly R; Idris I
    Am Heart J; 2018 Feb; 196():18-27. PubMed ID: 29421011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta-analysis and subgroup analysis of randomized controlled trials.
    Mannucci E; Dicembrini I; Nreu B; Monami M
    Diabetes Obes Metab; 2020 Feb; 22(2):203-211. PubMed ID: 31595657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study.
    Krishnan A; Schneider CV; Hadi Y; Mukherjee D; AlShehri B; Alqahtani SA
    Diabetologia; 2024 Mar; 67(3):483-493. PubMed ID: 38117293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study.
    Yang CT; Yang CY; Ou HT; Kuo S
    Cardiovasc Diabetol; 2020 Jun; 19(1):83. PubMed ID: 32534570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials.
    Marsico F; Paolillo S; Gargiulo P; Bruzzese D; Dell'Aversana S; Esposito I; Renga F; Esposito L; Marciano C; Dellegrottaglie S; Iesu I; Perrone Filardi P
    Eur Heart J; 2020 Sep; 41(35):3346-3358. PubMed ID: 32077924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLP-1RAs for Ischemic Stroke Prevention in Patients With Type 2 Diabetes Without Established Atherosclerotic Cardiovascular Disease.
    Yang YS; Chen HH; Huang CN; Hsu CY; Hu KC; Kao CH
    Diabetes Care; 2022 May; 45(5):1184-1192. PubMed ID: 35275992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagonlike peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in ischemic strokes with diabetes 2.
    Hastrup S; Hedegaard JN; Andersen G; Rungby J; Johnsen SP
    Eur J Neurol; 2024 Aug; 31(8):e16329. PubMed ID: 38715389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date.
    Brunton SA; Wysham CH
    Postgrad Med; 2020 Nov; 132(sup2):3-14. PubMed ID: 32815454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use.
    Rossing P; Agarwal R; Anker SD; Filippatos G; Pitt B; Ruilope LM; Fonseca V; Umpierrez GE; Caramori ML; Joseph A; Lambelet M; Lawatscheck R; Bakris GL;
    Diabetes Obes Metab; 2023 Feb; 25(2):407-416. PubMed ID: 36193847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular outcomes with GLP-1 receptor agonists vs. SGLT-2 inhibitors in patients with type 2 diabetes.
    Nørgaard CH; Starkopf L; Gerds TA; Vestergaard P; Bonde AN; Fosbøl E; Køber L; Wong ND; Torp-Pedersen C; Lee CJ
    Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(6):549-556. PubMed ID: 34215881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bariatric Metabolic Surgery vs Glucagon-Like Peptide-1 Receptor Agonists and Mortality.
    Dicker D; Sagy YW; Ramot N; Battat E; Greenland P; Arbel R; Lavie G; Reges O
    JAMA Netw Open; 2024 Jun; 7(6):e2415392. PubMed ID: 38848064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular safety and benefits of GLP-1 receptor agonists.
    Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
    Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials.
    Giugliano D; Maiorino MI; Bellastella G; Longo M; Chiodini P; Esposito K
    Diabetes Obes Metab; 2019 Nov; 21(11):2576-2580. PubMed ID: 31373167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is the steady-state concentration, duration of action, or molecular weight of GLP-1RA associated with cardiovascular and renal outcomes in type 2 diabetes?
    Bai S; Lin C; Jiao R; Cai X; Hu S; Lv F; Yang W; Zhu X; Ji L
    Eur J Intern Med; 2023 Mar; 109():79-88. PubMed ID: 36628824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular effectiveness of human-based vs. exendin-based glucagon like peptide-1 receptor agonists: a retrospective study in patients with type 2 diabetes.
    Longato E; Di Camillo B; Sparacino G; Tramontan L; Avogaro A; Fadini GP
    Eur J Prev Cardiol; 2021 Mar; 28(1):22-29. PubMed ID: 33624059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.